CRSP Earnings Date 2026
Crispr Therapeutics AG earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$56.52
-0.53% today
Earnings Metrics
EPS (TTM)
$-5.54
P/E Ratio
-13.0
Revenue Growth
47.7%
Market Cap
$5.4B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $-4.34 | $0.04B | $-0.37B |
| Q4 2023 | $-1.94 | $0.37B | $-0.15B |
Trading Around CRSP Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full CRSP Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is CRSP next earnings date?
CRSP (Crispr Therapeutics AG) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is CRSP earnings per share (EPS)?
CRSP's current earnings per share (EPS) is $-5.54. With a P/E ratio of -13.0, the market values each dollar of earnings at $-13.0.
How often does CRSP report earnings?
Like most publicly traded US companies, CRSP (Crispr Therapeutics AG) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does CRSP report earnings?
CRSP typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has CRSP performed in recent earnings?
In the most recent quarter (Q4 2024), CRSP reported EPS of $-4.34 on revenue of $0.04B.
What do analysts expect for CRSP earnings?
Analyst expectations for CRSP earnings can vary. The company has shown positive revenue growth of 47.7%. View the full analyst ratings page for detailed expectations.